Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.23
+0.05 (0.97%)
At close: Aug 25, 2026, 4:00 PM EDT
5.35
+0.12 (2.29%)
After-hours: Aug 25, 2026, 6:36 PM EDT
Immuneering Employees
Immuneering had 57 employees as of June 30, 2026. The number of employees increased by 3 or 5.56% compared to the same quarter last year.
Employees
57
Change
3
Growth
5.56%
Revenue / Employee
n/a
Profits / Employee
-$1,004,846
Market Cap
338.37M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 57 | 3 | 5.56% |
| Mar 31, 2026 | 55 | 1 | 1.85% |
| Dec 31, 2025 | 53 | -1 | -1.85% |
| Sep 30, 2025 | 54 | -12 | -18.18% |
| Jun 30, 2025 | 54 | -12 | -18.18% |
| Mar 31, 2025 | 54 | -11 | -16.92% |
| Sep 30, 2024 | 66 | -1 | -1.49% |
| Jun 30, 2024 | 66 | 0 | - |
| Mar 31, 2024 | 65 | -3 | -4.41% |
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Sep 30, 2023 | 67 | -7 | -9.46% |
| Jun 30, 2023 | 66 | -8 | -10.81% |
| Mar 31, 2023 | 68 | 0 | - |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Sep 30, 2022 | 74 | 38 | 105.56% |
| Jun 30, 2022 | 74 | 40 | 117.65% |
| Mar 31, 2022 | 68 | 36 | 112.50% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Abeona Therapeutics | 226 |
| ProQR Therapeutics | 187 |
| Sutro Biopharma | 128 |
| SAB Biotherapeutics | 86 |
| Orchestra BioMed Holdings | 86 |
| Agenus | 81 |
| DiaMedica Therapeutics | 35 |
IMRX News
- 19 days ago - Immuneering initiated with a Buy at H.C. Wainwright - TheFly
- 20 days ago - Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 20 days ago - Immuneering Earnings release: Q2 2026 - Filings
- 20 days ago - Immuneering Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Immuneering publishes preclinical data on atebimetinib in Cancer Research - TheFly
- 5 weeks ago - Publication in Cancer Research Details Atebimetinib's Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition - GlobeNewsWire
- 5 weeks ago - Immuneering Corporation Announces Grants of Inducement Awards - GlobeNewsWire
- 6 weeks ago - Immuneering initiated with an Overweight at Cantor Fitzgerald - TheFly